BioSpectrum
the business of Bio & Health Sciences
ASIA EDITION

Indonesia accelerates COVID-19 testing capability using Abbott's device

February 11, 2021 | News

Abbott's PanbioÃ¢â??Â¢ COVID-19 Ag Rapid Test Device molecular point-of-care technology and an antigen rapid test device that needs just a nasal swab, to detect active coronavirus infections at massive scale



Abbott's latest introductions in Indonesia include the Panbio™ COVID-19 Ag Rapid Test Device for the detection of the SARS-CoV-2 virus in people suspected of having COVID-19 and the ID NOW™ COVID-19 test platform for the fastest available molecular point-of-care detection of the novel coronavirus.

Quick, Reliable COVID-19 Tests with just a Nasal Swab

The Panbio COVID-19 Ag Rapid Test Device is a lateral flow assay for rapid, qualitative detection of the SARS-CoV-2 virus and is a reliable, affordable, portable and scalable option. Panbio COVID-19 Ag is CE-Marked and has received WHO Emergency Use Listing (EUL).

Individuals now have the option of a nasal swab for collection of specimens, making the process less invasive and more convenient. Abbott's rapid antigen test – which is authorized for use by healthcare professionals – requires no instrumentation and provides results as early as 15 minutes, making it a valuable tool for testing at massive scale in a variety of community settings. Negative results do not preclude COVID-19 infection and cannot be used as the sole basis for treatment or other management decisions.

The Panbio COVID-19 Ag test has been widely deployed in Europe, the Americas and Africa. In coordination with the Global Fund, the World Health Organization and the Bill & Melinda Gates Foundation, Abbott continues to make Panbio rapid antigen tests available to low- and middle-income countries.

Results from a clinical study by Abbott of 585 samples demonstrated that Panbio COVID-19 Ag test has a 91.4% sensitivity and 99.8% specificity on people who were suspected of exposure to COVID-19 or had symptoms in the last seven days[3].

Detecting Active Coronavirus Infections Using ID NOW

Abbott's ID NOW platform provides the fastest available molecular point-of-care detection of novel coronavirus, delivering results in 13 minutes or less, in a wide range of healthcare settings. As a point-of-care test to be used only by healthcare professionals or trained operators, the ID NOW COVID-19 test uses a naso-pharyngeal or throat swab (sample) and should be used near the patient. The swab should be placed directly into instrument, where it delivers fast and reliable results when compared to lab-based molecular polymerase chain reaction (PCR) instruments.

The ID NOW instrument detects the active presence of the SARS-CoV-2 virus by amplifying the virus' genomic structure (RNA) hundreds of millions of times. A positive result means that an individual has an active COVID-19 infection and is likely to be contagious and at risk of spreading the virus to others. In an interim post-authorization study evaluating 1,003 people, the ID NOW COVID-19 rapid test achieved overall performance of 93.3% positive agreement (sensitivity) and 98.4% negative agreement (specificity).